SLDB net incomeQ3 2026-$53.95M
SLDB net income was -$53.95M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$45.78M a year earlier. For the full fiscal 2025 it was -$174.32M, compared with -$124.70M in fiscal 2024.
Solid Biosciences Inc. (SLDB) financials
For the twelve months ended Sep 30, 2026, Solid Biosciences Inc. reported -$215.27M of net income.
- Net income, TTM
- -$215.27M
- Free cash flow, TTM
- -$200.30M
- Cash
- $125.97M
- Market cap
- $735.5M
FY2016FY2022
FY2016FY2025
FY2016FY2025
SLDB revenue and earnings growth
SLDB EPSQ3 2026-$0.36
SLDB diluted EPS was -$0.36 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$1.99.
SLDB free cash flowQ3 2026-$46.04M
SLDB free cash flow was -$46.04M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$33.56M a year earlier. For the full fiscal 2025 it was -$157.44M, compared with -$100.67M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $8.09M | $13.62M | $0 | $0 | $0 | $0 | $0 |
| Research and development | $140.32M | $96.43M | $76.56M | $78.42M | $58.74M | $64.88M | $94.74M | $57.97M | $39.91M | $20.12M |
| Selling, general and admin | $38.88M | $33.30M | $27.75M | $28.95M | $27.14M | $21.58M | $24.58M | $17.72M | $14.95M | $5.46M |
| Operating income | -$179.21M | -$129.73M | -$104.25M | -$106.45M | -$72.25M | -$88.41M | -$119.32M | -$75.69M | -$54.86M | -$25.58M |
| Interest expense | -$203.0K | $340.0K | $440.0K | - | - | - | - | - | - | - |
| Pre-tax income | -$174.20M | -$124.58M | - | - | - | - | - | - | - | - |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - | - |
| Net income | -$174.32M | -$124.70M | -$96.02M | -$85.98M | -$72.19M | -$88.29M | -$117.22M | -$74.80M | -$52.12M | -$21.54M |
| EPS, basic | -$1.99 | -$3.06 | -$4.83 | -$10.10 | -$10.14 | -$25.50 | -$2.91 | -$2.25 | -$2.88 | -$10.14 |
| EPS, diluted | -$1.99 | -$3.06 | -$4.83 | -$10.10 | -$10.14 | -$25.50 | -$2.91 | -$2.25 | -$2.88 | -$10.14 |
| Diluted shares | 87.5M | 40.8M | 19.9M | 8.5M | 7.1M | 3.5M | 40.3M | 33.3M | 13.6M | 1.7M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $59.90M | $82.19M | $75.85M | $157.22M | $119.14M | $155.07M | $76.04M | $86.37M | $52.15M | $7.84M |
| Current assets | $205.46M | $157.30M | $129.73M | $219.64M | $222.61M | $158.90M | $86.30M | $128.64M | $70.66M | - |
| Total assets | $232.54M | $188.66M | $164.94M | $260.25M | $232.38M | $171.17M | $103.47M | $139.60M | $76.19M | - |
| Current liabilities | $33.47M | $30.26M | $14.52M | $22.51M | $23.60M | $24.48M | $18.28M | $12.48M | $11.27M | - |
| Total liabilities | $52.53M | $51.42M | $38.46M | $48.59M | $24.17M | $39.08M | $23.42M | $14.41M | $11.27M | - |
| Shareholders' equity | $180.01M | $137.25M | $126.48M | $211.67M | $208.21M | $132.09M | $80.05M | $125.18M | -$59.26M | -$37.89M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$156.29M | -$100.01M | -$94.18M | -$97.98M | -$77.76M | -$56.60M | -$92.71M | -$70.20M | -$43.22M | -$20.12M |
| Capital expenditures | $1.15M | $654.0K | $1.51M | $3.02M | $1.28M | $899.0K | $4.39M | $7.78M | $2.28M | $392.0K |
| Free cash flow | -$157.44M | -$100.67M | -$95.69M | -$100.99M | -$79.05M | -$57.50M | -$97.10M | -$77.97M | -$45.50M | -$20.51M |
| Investing cash flow | -$58.45M | -$16.09M | $9.69M | $59.16M | -$91.09M | $6.60M | $24.52M | -$26.76M | $10.45M | -$4.05M |
| Financing cash flow | $194.45M | $122.44M | $3.12M | $74.83M | $134.99M | $128.70M | $57.88M | $131.51M | $77.08M | $3.42M |
| Stock-based compensation | $16.91M | $10.52M | $7.63M | $7.54M | $13.37M | $11.63M | $14.21M | $5.96M | $5.33M | $1.47M |
| Depreciation and amortization | $1.64M | $2.46M | $2.58M | $2.41M | $2.96M | $3.92M | $2.82M | - | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | -40.6% | - | - | - | - | - | - |
| Operating margin | - | - | - | -1315.2% | -530.5% | - | - | - | - | - |
| Net margin | - | - | - | -1062.3% | -530.0% | - | - | - | - | - |
| Free cash flow margin | - | - | - | -1247.7% | -580.4% | - | - | - | - | - |
| Return on equity | -96.8% | -90.9% | -75.9% | -40.6% | -34.7% | -66.8% | -146.4% | -59.8% | - | - |
| Return on assets | -75.0% | -66.1% | -58.2% | -33.0% | -31.1% | -51.6% | -113.3% | -53.6% | -68.4% | - |
| Current ratio | 6.14 | 5.20 | 8.94 | 9.76 | 9.43 | 6.49 | 4.72 | 10.31 | 6.27 | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $43.59M | $44.27M | $46.14M | $38.13M | $38.86M | $32.41M | $30.91M | $30.77M | $27.33M | $19.46M | $18.87M | $15.45M |
| Selling, general and admin | $14.06M | $13.12M | $11.17M | $11.27M | $9.20M | $9.28M | $9.14M | $9.13M | $7.86M | $8.33M | $7.99M | $6.81M |
| Operating income | -$57.66M | -$57.38M | -$57.31M | -$49.40M | -$48.06M | -$41.69M | -$40.05M | -$39.90M | -$35.18M | -$27.79M | -$26.86M | -$22.27M |
| Interest expense | - | - | - | $5.0K | -$336.0K | $60.0K | $68.0K | $75.0K | $82.0K | $88.0K | $95.0K | $101.0K |
| Income tax | - | - | - | - | - | - | - | - | - | $0 | $0 | $0 |
| Net income | -$53.95M | -$54.80M | -$56.74M | -$49.79M | -$45.78M | -$39.48M | -$39.28M | -$42.60M | -$32.73M | -$25.07M | -$24.30M | -$20.34M |
| EPS, basic | -$0.36 | -$0.38 | -$0.52 | - | -$0.48 | -$0.42 | -$0.59 | -$1.02 | -$0.79 | -$0.61 | -$0.64 | -$0.99 |
| EPS, diluted | -$0.36 | -$0.38 | -$0.52 | - | -$0.48 | -$0.42 | -$0.59 | -$1.02 | -$0.79 | -$0.61 | -$0.64 | -$0.99 |
| Diluted shares | 151.0M | 143.7M | 109.8M | - | 94.4M | 94.1M | 66.3M | - | 41.4M | 40.9M | 38.2M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $125.97M | $159.39M | $297.10M | $59.90M | $61.36M | $138.93M | $210.63M | $82.19M | $64.39M | $95.85M | $117.57M | $75.85M |
| Current assets | $365.19M | $395.11M | $396.79M | $205.46M | $244.85M | $278.64M | $313.41M | $157.30M | $179.49M | $197.61M | $214.19M | $129.73M |
| Total assets | $389.90M | $420.58M | $422.89M | $232.54M | $273.91M | $308.29M | $343.90M | $188.66M | $211.83M | $230.98M | $248.69M | $164.94M |
| Current liabilities | $30.45M | $28.58M | $30.28M | $33.47M | $36.34M | $29.85M | $28.78M | $30.26M | $22.85M | $14.69M | $14.34M | $14.52M |
| Total liabilities | $47.79M | $46.51M | $48.76M | $52.53M | $55.97M | $50.00M | $49.44M | $51.42M | $44.80M | $37.74M | $37.97M | $38.46M |
| Shareholders' equity | $342.11M | $374.07M | $374.13M | $180.01M | $217.95M | $258.29M | $294.46M | $137.25M | $167.02M | $193.25M | $210.72M | $126.48M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$45.55M | -$52.59M | -$47.23M | -$53.55M | -$33.47M | -$37.41M | -$31.85M | -$29.64M | -$23.71M | -$21.47M | -$25.19M | -$20.82M |
| Capital expenditures | $498.0K | $150.0K | $165.0K | $565.0K | $85.0K | $377.0K | $126.0K | $204.0K | $15.0K | $286.0K | $149.0K | $90.0K |
| Free cash flow | -$46.04M | -$52.74M | -$47.40M | -$54.12M | -$33.56M | -$37.79M | -$31.98M | -$29.85M | -$23.72M | -$21.75M | -$25.34M | -$20.91M |
| Investing cash flow | -$3.76M | -$133.59M | $44.76M | $47.01M | -$45.27M | -$32.73M | -$27.46M | $38.57M | -$10.99M | -$5.18M | -$38.49M | $45.30M |
| Financing cash flow | $15.88M | $48.47M | $239.03M | $5.14M | $1.18M | -$1.60M | $189.73M | $6.94M | $3.26M | $5.00M | $107.24M | $505.0K |
| Stock-based compensation | $6.15M | $5.62M | $5.15M | $6.50M | $3.93M | $3.15M | $3.34M | $3.82M | $3.00M | $2.09M | $1.61M | $1.94M |
| Depreciation and amortization | $416.0K | $391.0K | $395.0K | $467.0K | $376.0K | $386.0K | $407.0K | $488.0K | $405.0K | $1.24M | $327.0K | - |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 11.99 | 13.82 | 13.10 | 6.14 | 6.74 | 9.34 | 10.89 | 5.20 | 7.85 | 13.45 | 14.94 | 8.94 |
Source: XBRL data Solid Biosciences Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
SLDB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| SLDB | - | - | -$215.27M | - | $735.5M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.23B | -27.6% | -$3.15B | -141.4% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
SLDB FAQ
5 questionsIs SLDB profitable?
No. Solid Biosciences Inc. reported a net loss of $215.27M for the twelve months ended Sep 30, 2026.How much cash and debt does SLDB have?
Solid Biosciences Inc. reported $125.97M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is SLDB free cash flow?
Solid Biosciences Inc. generated -$200.30M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$198.92M less capital expenditures.When did SLDB last report financial results?
The latest statements here come from Solid Biosciences Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.Where does this SLDB financial data come from?
Quantisnow builds these statements from the structured XBRL data Solid Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.